by B2i | Nov 20, 2023 | Press Releases
JUPITER, Fla., Nov. 20, 2023 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein...
by B2i | Nov 8, 2023 | Press Releases
Received an upfront payment of $0.6 million in October for product development and licensing of our Dapibus™ platform for animal-free dairy enzyme products DYAI-100 Phase 1 clinical trial top-line results expected in December 2023 New research collaboration with...
by B2i | Oct 30, 2023 | Press Releases
JUPITER, Fla., Oct. 30, 2023 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...
by B2i | Oct 25, 2023 | Press Releases
JUPITER, Fla., Oct. 25, 2023 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
by B2i | Oct 9, 2023 | Press Releases
JUPITER, Fla., Oct. 09, 2023 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
